Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zuozhang Yang is active.

Publication


Featured researches published by Zuozhang Yang.


Molecular Cancer | 2015

Apoptosis, autophagy, necroptosis, and cancer metastasis

Zhenyi Su; Zuozhang Yang; Yongqing Xu; Yongbin Chen; Qiang Yu

Metastasis is a crucial hallmark of cancer progression, which involves numerous factors including the degradation of the extracellular matrix (ECM), the epithelial-to-mesenchymal transition (EMT), tumor angiogenesis, the development of an inflammatory tumor microenvironment, and defects in programmed cell death. Programmed cell death, such as apoptosis, autophagy, and necroptosis, plays crucial roles in metastatic processes. Malignant tumor cells must overcome these various forms of cell death to metastasize. This review summarizes the recent advances in the understanding of the mechanisms by which key regulators of apoptosis, autophagy, and necroptosis participate in cancer metastasis and discusses the crosstalk between apoptosis, autophagy, and necroptosis involved in the regulation of cancer metastasis.


BMC Medical Genetics | 2014

Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data

Zuozhang Yang; Yongbin Chen; Yu Fu; Yihao Yang; Ya Zhang; Yanjin Chen; Dongqi Li

BackgroundTo uncover the genes involved in the development of osteosarcoma (OS), we performed a meta-analysis of OS microarray data to identify differentially expressed genes (DEGs) and biological functions associated with gene expression changes between OS and normal control (NC) tissues.MethodsWe used publicly available GEO datasets of OS to perform a meta-analysis. We performed Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Protein-Protein interaction (PPI) networks analysis.ResultsEight GEO datasets, including 240 samples of OS and 35 samples of controls, were available for the meta-analysis. We identified 979 DEGs across the studies between OS and NC tissues (472 up-regulated and 507 down-regulated). We found GO terms for molecular functions significantly enriched in protein binding (GO: 0005515, P = 3.83E-60) and calcium ion binding (GO: 0005509, P = 3.79E-13), while for biological processes, the enriched GO terms were cell adhesion (GO:0007155, P = 2.26E-19) and negative regulation of apoptotic process (GO: 0043066, P = 3.24E-15), and for cellular component, the enriched GO terms were cytoplasm (GO: 0005737, P = 9.18E-63) and extracellular region (GO: 0005576, P = 2.28E-47). The most significant pathway in our KEGG analysis was Focal adhesion (P = 5.70E-15). Furthermore, ECM-receptor interaction (P = 1.27E-13) and Cell cycle (P = 4.53E-11) are found to be highly enriched. PPI network analysis indicated that the significant hub proteins containing PTBP2 (Degree = 33), RGS4 (Degree = 15) and FXYD6 (Degree = 13).ConclusionsOur meta-analysis detected DEGs and biological functions associated with gene expression changes between OS and NC tissues, guiding further identification and treatment for OS.


Cell Death and Disease | 2016

Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma

Zuozhang Yang; Xiaojuan Li; Yihao Yang; Zewei He; Xin Qu; Ya Zhang

Long noncoding RNAs (lncRNAs) are a class of non-protein-coding molecules longer than 200 nucleotides that are involved in the development and progression of many types of tumors. Numerous lncRNAs regulate cell proliferation, metastasis, and chemotherapeutic drug resistance. Osteosarcoma is one of the main bone tumor subtypes that poses a serious threat to adolescent health. We summarized how lncRNAs regulate osteosarcoma progression, invasion, and drug resistance, as well as how lncRNAs can function as biomarkers or independent prognostic indicators with respect to osteosarcoma therapy.


Oncotarget | 2016

Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment

Jing Li; Zuozhang Yang; Yi Li; Junfeng Xia; Dongqi Li; Huiling Li; Mingyan Ren; Yedan Liao; Shunling Yu; Yanjin Chen; Yihao Yang; Ya Zhang

Osteosarcoma is the most common primary bone tumor in children and adolescents. Although combined therapy including surgery and multi-agent chemotherapy have resulted in great improvements in the overall survival of patients, chemoresistance remains an obstacle for the treatment of osteosarcoma. Molecular targets or effective agents that are actively involved in cell death including apoptosis, autophagy and necroptosis have been studied. We summarized how these agents (novel compounds, miRNAs, or proteins) regulate apoptotic, autophagic and necroptotic pathways; and discussed the current knowledge on the role of these new agents in chemotherapy resistance in osteosarcoma.


Journal of bone oncology | 2016

A comparative study between limb-salvage and amputation for treating osteosarcoma.

Xiaojuan Li; Ya Zhang; Shanshan Wan; Huiling Li; Dongqi Li; Junfeng Xia; Zhongqin Yuan; Mingyan Ren; Shunling Yu; Su Li; Yihao Yang; Lei Han; Zuozhang Yang

Purpose Osteosarcoma is an aggressive malignant neoplasm, and conflicting findings have been reported on the survival and function recovery in osteosarcoma patients experiencing limb salvage or amputation. In the present study, we compared clinical outcomes regarding limb salvage surgery vs. amputation for osteosarcoma patients by a meta-analysis. Method Literature search was conducted in CNKI, Medline, Embase, the Cochrane Database, and Web of Sciences, and the quality of included studies was evaluated based on Newcastle-Ottawa scale quality assessment. Odds ratio and 95% confidence interval of the local recurrence, 5-year overall survival, and metastasis occurrence were calculated. Results 17 articles were included according to selection criteria. There were 1343 patients in total derived from these studies. Our result showed that there was no significant difference between limb salvage surgery and amputation with respect to local recurrence, and patients with limb salvage surgery had a higher 5-year overall survival, and a lower metastasis occurrence. Conclusions The present study provided more comprehensive evidences to support limb salvage surgery as an optimal treatment of osteosarcoma patients.


Theranostics | 2017

Circular RNAs: Regulators of Cancer-Related Signaling Pathways and Potential Diagnostic Biomarkers for Human Cancers

Zuozhang Yang; Lin Xie; Lei Han; Xin Qu; Yihao Yang; Ya Zhang; Zewei He; Yu Wang; Jing Li

Circular RNAs (circRNAs) are newly discovered endogenous non-coding RNAs featuring structural stability, high abundance, and tissue-specific expression. CircRNAs are prevalent and conserved in mammalian cells. They are involved in cellular processes and regulate gene expression at the transcriptional or post-transcriptional level by interacting with microRNAs (miRNAs) and other molecules. Recent studies have shown that circRNAs play an important role in the progression of various human diseases including atherosclerosis, nervous system disorders, diabetes, and cancer. In this review, we summarize the advances on endogenous circRNAs in eukaryotic cells and elucidate their diagnostic and prognostic significance in human cancers. Especially, we highlight the involvement of circRNAs in signal transduction pathways as well as their clinical potential to serve as biomarkers.


Journal of bone oncology | 2016

P62: An emerging oncotarget for osteolytic metastasis.

Jing Zhang; Zuozhang Yang; Jian Dong

Bone metastasis occurs in the majority of late-stage tumors with poor prognosis. It is mainly classified as osteoblastic metastasis and osteolytic metastasis. The pathogenesis of osteolytic metastasis is a “vicious cycle” between tumor cells and bone cells (primarily the osteoclasts), which is mediated by secretory factors. The P62 adapter protein is a versatile multitasker between tumor cells and bone cells. The overexpression of P62 has been detected among a variety of tumors, playing positive roles in both tumorigenesis and metastasis. Moreover, P62 is an important modulator of the osteoclastogenesis pathway. Therefore, the ability of P62 to modulate tumors and osteoclasts suggests that it may be a feasible oncotarget for bone metastasis, especially for osteolytic metastasis. Recent research has shown that a P62 DNA vaccine triggered effective anti-tumor, anti-metastatic and anti-osteoporotic activities. Growing lines of evidence point to P62 as an emerging oncotarget for osteolytic metastasis. In this review, we outline the different roles of P62 in tumor cells and osteoclasts, focusing on the P62-related signaling pathway in key steps of osteolytic metastasis, including tumorigenesis, metastasis and osteoclastogenesis. Finally, we discuss the newest observations on P62 as an oncotarget for osteolytic metastasis treatment.


World Journal of Surgical Oncology | 2015

Status and prospects of percutaneous vertebroplasty combined with 125I seed implantation for the treatment of spinal metastases

Lin Xie; Yanjin Chen; Ya Zhang; Zuozhang Yang; Zhaoxin Zhang; Lida Shen; Zhongqin Yuan; Mingyan Ren

Metastatic spinal tumours are the most common type of bone metastasis. Various methods have been used to treat metastatic spinal lesions, including radiotherapy, chemotherapy, isotope therapy, bisphosphonate therapy, analgesics, and surgery. Conservative treatments such as radiotherapy and chemotherapy are not appropriate and usually are ineffective in patients with vertebral fractures and/or spinal instability. Minimally invasive surgical treatments using non-vascular interventional technology, such as percutaneous vertebroplasty (PVP), have been successfully performed in the clinical setting. PVP is a non-invasive procedure that creates small wounds and is usually associated with only minor complications. In the present study, we will review the clinical status and prospects for the use PVP combined with 125I seed implantation (PVPI) to treat spinal metastases. The scientific evidence for this treatment, including safety, efficacy, and outcome measures, as well as comparisons with other therapies, was analysed in detail. PVPI effectively alleviates pain in metastatic spinal tumour patients, and the use of interstitial 125I seed implants can enhance the clinical outcomes. In conclusion, PVPI is a safe, reliable, effective, and minimally invasive treatment. The techniques of PVP and 125I seed implantation complement each other and strengthen the treatment’s effect, presenting a new alternative treatment for spinal metastases with potentially wide application.


EBioMedicine | 2017

Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy

Zuozhang Yang; Zhenyi Su; Judy Park DeWitt; Lin Xie; Yongbin Chen; Xiaojuan Li; Lei Han; Dongqi Li; Junfeng Xia; Ya Zhang; Yihao Yang; Congguo Jin; Jing Zhang; Su Li; Kun Li; Zhiping Zhang; Xin Qu; Zewei He; Yanjin Chen; Yan Shen; Mingyan Ren; Zhongqin Yuan

Bone is one of the most preferred sites of metastasis in lung cancer. Currently, bisphosphonates and denosumab are major agents for controlling tumor-associated skeletal-related events (SREs). However, both bisphosphonates and denosumab significantly increase the risk for jaw osteonecrosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the most frequently prescribed cholesterol-lowering agents, have been reported to inhibit tumor progression and induce autophagy in cancer cells. However, the effects of statin and role of autophagy by statin on bone metastasis are unknown. In this study, we report that fluvastatin effectively prevented lung adenocarcinoma bone metastasis in a nude mouse model. We further reveal that fluvastatin-induced anti-bone metastatic property was largely dependent on its ability to induce autophagy in lung adenocarcinoma cells. Atg5 or Atg7 deletion, or 3-methyadenine (3-MA) or Bafilomycin A1 (Baf A1) treatment prevented the fluvastatin-induced suppression of bone metastasis. Furthermore, we reveal that fluvastatin stimulation increased the nuclear p53 expression, and fluvastatin-induced autophagy and anti-bone metastatic activity were mostly dependent on p53.


Oncotarget | 2016

Identification of differentially expressed genes in the development of osteosarcoma using RNA-seq

Yihao Yang; Ya Zhang; Xin Qu; Junfeng Xia; Dongqi Li; Xiaojuan Li; Yu Wang; Zewei He; Su Li; Yonghong Zhou; Lin Xie; Zuozhang Yang

Objective Osteosarcoma (OS) is a malignant bone tumor with high morbidity in young adults and adolescents. This study aimed to discover potential early diagnosis biomarkers in OS. Results In total, 111 differentially expressed genes (DEGs) were identified in primary OS compared with normal controls and 235 DEGs were identified in metastatic OS compared with primary OS. AURKB and PPP2R2B were the significantly up-regulated and down-regulated hub proteins, respectively, in the PPI protein-protein network (PPI) network of primary OS. ISG15 and BTRC were the significantly up-regulated and down-regulated hub proteins, respectively, in the network of metastatic OS. The DEGs in metastatic OS compared with primary OS were significantly enriched in the arachidonic acid metabolism, malaria, and chemokine signaling pathways. Finally, we employed quantitative real-time polymerase chain reaction (qRT-PCR) to validate the expression levels of candidate DEGs and the results indicated that our bioinformatics approach was acceptable. Materials and Methods The mRNA expression profiling of 20 subjects was obtained through high-throughput RNA-sequencing. DEGs were identified between primary OS and normal Control, and between primary OS and metastatic OS, respectively. Functional annotation and PPI networks were used to obtain insights into the functions of DEGs. qRT-PCR was performed to detect the expression levels of dysregulated genes in OS. Conclusions Our work might provide groundwork for the further exploration of tumorigenesis and metastasis mechanisms of OS.

Collaboration


Dive into the Zuozhang Yang's collaboration.

Top Co-Authors

Avatar

Ya Zhang

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Yihao Yang

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Dongqi Li

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Lei Han

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Lin Xie

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Junfeng Xia

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Mingyan Ren

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Zewei He

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Xiaojuan Li

Kunming Medical University

View shared research outputs
Top Co-Authors

Avatar

Yanjin Chen

Kunming Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge